Style | Citing Format |
---|---|
MLA | Afshar PT, et al.. "Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis." Current Pharmacogenomics and Personalized Medicine, vol. 20, no. 1, 2023, pp. 57-71. |
APA | Afshar PT, Taherian Z, Bakhtiyari R, Rami F, Etemadifar M, Salehi M (2023). Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis. Current Pharmacogenomics and Personalized Medicine, 20(1), 57-71. |
Chicago | Afshar PT, Taherian Z, Bakhtiyari R, Rami F, Etemadifar M, Salehi M. "Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis." Current Pharmacogenomics and Personalized Medicine 20, no. 1 (2023): 57-71. |
Harvard | Afshar PT et al. (2023) 'Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis', Current Pharmacogenomics and Personalized Medicine, 20(1), pp. 57-71. |
Vancouver | Afshar PT, Taherian Z, Bakhtiyari R, Rami F, Etemadifar M, Salehi M. Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis. Current Pharmacogenomics and Personalized Medicine. 2023;20(1):57-71. |
BibTex | @article{ author = {Afshar PT and Taherian Z and Bakhtiyari R and Rami F and Etemadifar M and Salehi M}, title = {Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis}, journal = {Current Pharmacogenomics and Personalized Medicine}, volume = {20}, number = {1}, pages = {57-71}, year = {2023} } |
RIS | TY - JOUR AU - Afshar PT AU - Taherian Z AU - Bakhtiyari R AU - Rami F AU - Etemadifar M AU - Salehi M TI - Riboflavin and Histidine Metabolisms Are Two Key Pathways Related to the Clinically Isolated Syndrome (Cis): A Wgcna-Based in Silico Analysis JO - Current Pharmacogenomics and Personalized Medicine VL - 20 IS - 1 SP - 57 EP - 71 PY - 2023 ER - |